Silk Road Medical, Inc. news

Silk Road Medical Strengthens Leadership Team

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s current Chief Financial

Sep. 26, yyyy

Silk Road Medical Announces FDA Approval of Expanded Indications for the ENROUTE Transcarotid Stent System

Silk Road Medical, Inc.?(Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that that the U.S. Food and Drug Administration (FDA) approved expanded indications for the ENROUTE stent to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiological criteria that put them at high risk of complications from more invasive surg

May. 2, yyyy

First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid disease, including patients undergoing carotid endarterectomy (CEA) and transcarotid artery revascularization (TCAR), will be presented at the upcoming Society for Vascular Surgery 2021 Vascular Annual Meeting (VAM), August 18 –21 at the San Diego Conventio

Jul. 6, yyyy

Silicon Valley-Based Silk Road Medical Announces Expansion to MSP Region

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, recently announced the opening of a new office in Plymouth, Minnesota, to accommodate growing demand for TransCarotid Artery Revascularization (TCAR) and to access the local talent pool of aspiring and experienced med tech professionals.

“We continue to invest in our long-term growth and are excited to expand our operations to include a facility in Plymouth.

Jun. 22, yyyy

Study Published in JAMA Finds Hospital Availability of TCAR Associated with an Improvement in Overall Outcomes for Carotid Revascularization

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open.

The study found the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events (MACE), a composite of in-hospital stroke, myocardial infarction, or de

Feb. 25, yyyy

Silk Road Medical Names Rick Anderson to Board of Directors

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors.

Anderson brings over 30 years of senior executive leadership experience in the medical device industry. He is the Chairman and Managing Director of Revival Healthcare Capital, a sustainable, high im

Oct. 1, yyyy